So frustrating to know that AMBS identified this c
Post# of 30028
My concern is that eventually the AMBS IP surrounding MANF will get sold off or transferred to some other investor/bio for pennies and then they will immediately start promoting all this impressive research surrounding the compound, begin some human trials, and get an immediate market cap of $500M-1B plus.
I sincerely hope I am wrong and continue to hold plenty of shares in the hope that I am wrong, but as more and more time passes that begins to look increasingly like the eventual outcome. If that were to happen, I think common shareholders would get nothing or next to nothing.